USPTO Demands Neat DNA Patents: Sequence Up!
Published Date: 10/24/2025
Notice
Summary
The USPTO is asking for feedback on how it collects info from patent applications that include DNA or protein sequences. This review aims to keep the process smooth and reduce paperwork for inventors and companies. If you’re involved in biotech patents, now’s the time to share your thoughts before November 24, 2025!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Sequence Listings Required in Patent Filings
If your patent application discloses DNA (nucleotide) or protein (amino acid) sequences, you must include a separate sequence listing part with the application under the rules set out in 37 CFR 1.831 (for applications filed on or after July 1, 2022) or 37 CFR 1.821(a) (for applications filed on or before June 30, 2022). The USPTO uses these sequence listings during patent examination and for pre-grant publication, and applicants may submit them for both U.S. and international applications.
Paperwork Time and Cost Estimate
The USPTO estimates this information collection will have about 30,000 annual respondents and 30,000 annual responses, with each response taking about 6 hours to complete. The notice estimates a total annual respondent burden of 180,000 hours and an estimated total annual non-hourly cost burden of $336,973.
CRF Submission for Older Application Amendments
For sequence listings filed as 37 CFR 1.825 amendments in applications with a filing date on or before June 30, 2022, the submission may also require a new or substitute computer readable form (CRF) copy of the sequence listing under 37 CFR 1.821(e) and 1.824, incorporated as part of the amendment under 37 CFR 1.825(a)(5)(ii) or (b)(6)(ii).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-19649, Corporate Senior Executive Management Office Notice of Performance Review Board Members
The Corporate Senior Executive Management Office has announced the new members of its Performance Review Board, the team that evaluates top executives' work. This update affects senior leaders and ensures fair, timely reviews to keep leadership strong. No changes to pay or deadlines were mentioned, but the board’s fresh lineup means executive reviews stay sharp and on track.
Next: 2025-19651, Annual Pay Ranges for Physicians, Dentists, Podiatrists, and Optometrists of the Veterans Health Administration (VHA)
The VA is updating pay ranges for doctors, dentists, podiatrists, and now optometrists working in Veterans Health Administration. Starting December 28, 2025, optometrists will be included in the pay system to help attract and keep top talent for our veterans. This change mixes base pay, market pay, and performance pay to reward skills, location, and great work.